Ernesto joined ClearPoint Neuro in March 2021. He brings over 20 years of experience in translational neuroscience with direct pre-clinical neurosurgery expertise delivering therapeutics to the brain, spinal cord and cerebrospinal fluid. He has over 16 years of combined experience in the field of AAV gene therapy, stem cell therapy, image-guided platforms, small/larger molecules and neurodegenerative disorders. Dr. Salegio has served as a study director for more than 11 years in nonGLP studies, as well as in safety/tox GLP studies and has worked with industry and academic partners from study conception to IND-approval. During his career, he has led cross-functional teams, strategic partnerships, studies investigating novel therapeutics (AAV libraries), biomarker identification indicative of therapeutic benefit and device development of MRI-compatible hardware. He has authored more than 32 peer-reviewed publications and holds a bachelor’s in Behavioral Psychology, a Bachelor’s in Neuroscience (with honors) and a Ph.D. in Neuroscience/Inflammation from Flinders University of South Australia.
Ernesto Salegio, PhD
Vice President, Segment Leader Translational & Pre-Clinical Research